Allogeneic MHC gene transfer enhances antitumor activity of allogeneic hematopoietic stem cell transplantation without exacerbating graft-versus-host disease

Clinical Cancer Research

Volumn 12, Issue 7 I, 2006, Pages 2208-2215

  Ohashi, Masaki ^a,b   Kobayashi, Akihiko ^a   Hara, Hidehiko ^a   Miura, Yoshiaki ^a   Yoshida, Kimiko ^a   Kushida, Miwa ^a   Ikarashi, Yoshinori ^a   Mandai, Masaki ^c   Kitajima, Masaki ^b   Yoshida, Teruhiko ^a   Aoki, Kazunori ^a  

^a NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

^b KEIO UNIVERSITY   (Japan)

^c KYOTO UNIVERSITY HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

MAJOR HISTOCOMPATIBILITY ANTIGEN; MINOR HISTOCOMPATIBILITY ANTIGEN; PLASMID DNA; TUMOR ANTIGEN; VIRUS VECTOR;

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CANCER INHIBITION; CARCINOGENICITY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; COLON CANCER; CONTROLLED STUDY; CYTOLYSIS; CYTOTOXICITY; DISEASE EXACERBATION; DRUG EFFICACY; FEMALE; GENE TRANSFER; GENETIC TRANSDUCTION; GRAFT VERSUS HOST REACTION; IMMUNE RESPONSE; MOUSE; NONHUMAN; PRIORITY JOURNAL; ROUS SARCOMA ONCOVIRUS; T LYMPHOCYTE; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY;

ANIMALS; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; CELL PROLIFERATION; COLONIC NEOPLASMS; DISEASE MODELS, ANIMAL; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; GENE THERAPY; GENE TRANSFER TECHNIQUES; GRAFT VS HOST DISEASE; GRAFT VS TUMOR EFFECT; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISTOCOMPATIBILITY ANTIGENS CLASS I; KIDNEY NEOPLASMS; MICE; MICE, INBRED BALB C; MICE, INBRED DBA; NEOPLASM TRANSPLANTATION; SPECIES SPECIFICITY; STRUCTURE-ACTIVITY RELATIONSHIP; TRANSPLANTATION, HOMOLOGOUS; TRANSPLANTATION, ISOGENEIC;

EID: 33646268197     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-05-2657     Document Type: Article

References (43)

1. Childs R, Chernoff A, Contentin N, et al. Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation. N Engl J Med 2000;343:750-8.
2. Ueno NT, Cheng YC, Rondon G, et al. Rapid induction of complete donor chimerism by the use of a reduced-intensity conditioning regimen composed of fludarabine and melphalan in allogeneic stem cell transplantation for metastatic solid tumors. Blood 2003;102:3829-36.
3. Bishop MR, Fowler DH, Marchigiani D, et al. Allogeneic lymphocytes induce tumor regression of advanced metastatic breast cancer. J Clin Oncol 2004;22:3886-92.
4. Kanda Y, Komatsu Y, Akahane M, et al. Graft-versus-tumor effect against advanced pancreatic cancer after allogeneic reduced-intensity stem cell transplantation. Transplantation 2005;79:821-7.
5. Bay JO, Fleury J, Choufi B, et al. Allogeneic hematopoietic stem cell transplantation in ovarian carcinoma: results of five patients. Bone Marrow/Transplant 2002;30:95-102.
6. Kurokawa T, Fischer K, Bertz H, Hoegerle S, Finke J, Mackensen A. In vitro and in vivo characterization of graft-versus-tumor responses in melanoma patients after allogeneic peripheral blood stem cell transplantation. Int J Cancer 2002;101:52-60.
7. Moscardo F, Martinez JA, Sanz GF, et al. Graft-versus-tumour effect in non-small-cell lung cancer after allogeneic peripheral blood stem cell transplantation. Br J Haematol 2000;111:708-10.
8. Zetterquist H, Hentschke P, Thorne A, et al. A graft-versus-colonic cancer effect of allogeneic stem cell transplantation. Bone Marrow Transplant 2001;28:1161-6.
9. Plautz GE, Yang ZY, Wu BY, Gao X, Huang L, Nabel GJ. Immunotherapy of malignancy by in vivo gene transfer into tumors. Proc Natl Acad Sci USA 1993;90:4645-9.
10. Nabel GJ, Nabel EG, Yang ZY, et al. Direct gene transfer with DNA-liposome complexes in melanoma: expression, biologic activity, and lack of toxicity in humans. Proc Natl Acad Sci U S A 1993;90:11307-11.
11. Nabel GJ, Gordon D, Bishop DK, et al. Immune response in human melanoma after transfer of an allogeneic class I major histocompatibility complex gene with DNA-liposome complexes. Proc Natl Acad Sci U S A 1996;93:15388-93.
12. 2-microglobulin DNA-liposome complex, in patients with metastatic melanoma. Clin Cancer Res 2001;7:2285-91.
13. Rini BI, Selk LM, Vogelzang NJ. Phase I study of direct intralesional gene transfer of HLA-B7 into metastatic renal carcinoma lesions. Clin Cancer Res 1999;5:2766-72.
14. Rubin J, Galanis E, Pitot HC, et al. Phase I study of immunotherapy of hepatic metastases of colorectal carcinoma by direct gene transfer of an allogeneic histocompatibility antigen, HLA-B7. Gene Ther 1997;4:419-25.
15. Gleich LL, Gluckman JL, Armstrong S, et al. Alloantigen gene therapy for squamous cell carcinoma of the head and neck: results of a phase-1 trial. Arch Otolaryngol Head Neck Surg 1998;124:1097-104.
16. Gleich LL, Gluckman JL, Nemunaitis J, et al. Clinical experience with HLA-B7 plasmid DNA/lipid complex in advanced squamous cell carcinoma of the head and neck. Arch Otolaryngol Head Neck Surg 2001;127:775-9.
17. Mapara MY, Sykes M. Tolerance and cancer: mechanisms of tumor evasion and strategies for breaking tolerance. J Clin Oncol 2004;22:1136-51.
18. Cooke KR, Kobzik L, Martin TR, et al. An experimental model of idiopathic pneumonia syndrome after bone marrow transplantation: I. The roles of minor H antigens and endotoxin. Blood 1996;88:3230-9.
19. Nakayama E, Uenaka A. Effect of in vivo administration of Lyt antibodies-Lyt phenotype of T cells in lymphoid tissues and blocking of tumor rejection. J Exp Med 1985;161:345-55.
20. Witherspoon RP, Storb R, Ochs HD, et al. Recovery of antibody production in human allogeneic marrow graft recipients: influence of time posttransplantation, the presence or absence of chronic graft-versus-host disease, and antithymocyte globulin treatment. Blood 1981;58:360-8.
21. Seddik M, Seemayer TA, Lapp WS. The graft-versus-host reaction and immune function. I. T helper cell immunodeficiency associated with graft-versus-host-induced thymic epithelial cell damage. Transplantation 1984;37:281-6.
22. Lum LG. The kinetics of immune reconstitution after human marrow transplantation. Blood 1987;69:369-80.
23. Mapara MY, Kim YM, Wang SP, Bronson R, Sachs DH, Sykes M. Donor lymphocyte infusions mediate superior graft-versus-leukemia effects in mixed compared to fully allogeneic chimeras: a critical role for host antigen-presenting cells. Blood 2002;100:1903-9.
24. Billiau AD, Fevery S, Rutgeerts O, Landuyt W, Waer M. Crucial role of timing of donor lymphocyte infusion in generating dissociated graft-versus-host and graft-versus-leukemia responses in mice receiving allogeneic bone marrow transplants. Blood 2002;100:1894-902.
25. + Tcells by virtue of their receptor β loci sequences. Proc Natl Acad Sci U S A 2003;100:1180-4.
26. + T cells are defective in mediating acute graft-versus-host disease but retain graft-versus-leukemia activity. Blood 2004;103:3970-8.
27. Anderson LD, Jr., Savary CA, Mullen CA. Immunization of allogeneic bone marrow transplant recipients with tumor cell vaccines enhances graft-versus-tumor activity without exacerbating graft-versus-host disease. Blood 2000;95:2426-33.
28. Teshima T, Mach N, Hill GR, et al. Tumor cell vaccine elicits potent antitumor immunity after allogeneic T-cell-depleted bone marrow transplantation. Cancer Res 2001;61:162-71.
29. Luznik L, Slansky JE, Jalla S, et al. Successful therapy of metastatic cancer using tumor vaccines in mixed allogeneic bone marrow chimeras. Blood 2003;101:1645-52.
30. Anderson LD, Jr., Mori S, Mann S, Savary CA, Mullen CA. Pretransplant tumor antigen-specific immunization of allogeneic bone marrow transplant donors enhances graft-versus-tumor activity without exacerbation of graft-versus-host disease. Cancer Res 2000;60:5797-802.
31. Teshima T, Hill GR, Pan L, et al. IL-11 separates graft-versus-leukemia effects from graft-versus-host disease after bone marrow transplantation. J Clin Invest 1999;104:317-25.
32. + regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation. Nat Med 2003;9:1144-50.
33. + regulatory T cells favor immune reconstitution and control graft-versus-host disease while maintaining graft-versus-leukemia. J Clin Invest 2003;112:1688-96.
34. Matte CC, Liu J, Cormier J, et al. Donor APCs are required for maximal GVHD but not for GVL. Nat Med 2004;10:987-92.
35. Schmaltz C, Alpdogan O, Horndasch KJ, et al. Differential use of Fas ligand and perforin cytotoxic pathways by donor T cells in graft-versus-host disease and graft-versus-leukemia effect. Blood 2001;97:2886-95.
36. Zoller M. Immunotherapy of cancer for the elderly patient: does allogeneic bone marrow transplantation after nonmyeloablative conditioning provide a new option? Cancer Immunol Immunother 2004;53:659-76.
37. + T cell-mediated graft-versus-tumor effect that is independent of the recognition of alloantigenic tumor targets. Blood 2004;104:1210-6.
38. + cytotoxic T-lymphocyte clones from a patient with severe graft-versus-host disease after allogeneic bone marrow transplantation: implications for graft-versus-leukemia reactivity. Blood 1995;86:2821-8.
39. Anderson BE, McNiff JM, Jain D, Blazar BR, Shlomchik WD, Shlomchik MJ. Distinct roles for donor- and host-derived antigen-presenting cells and costimulatory molecules in murine chronic graft-versus-host disease: requirements depend on target organ. Blood 2005;105:2227-34.
40. Rocha B, Grandien A, Freitas AA. Anergy and exhaustion are independent mechanisms of peripheral T cell tolerance. J Exp Med 1995;181:993-1003.
41. Huang AYC, Gulden PH, Woods AS, et al. The immunodominant major histocompatibility complex class I-restricted antigen of a murine colon tumor derives from an endogenous retroviral product. Proc Natl Acad Sci U S A 1996;93:9730-5.
42. Childs R, Clave E, Contentin N, et al. Engraftment kinetics after nomyeloablative allogeneic peripheral blood stem cell transplantation: full donor T-cell chimerism precedes alloimmune responses. Blood 1999;94:3234-41.
43. McSweeney PA, Niederwieser D, Shizuru JA, et al. Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. Blood 2001;97:3390-400.